Pharmaceutical & Biotech
News and Insights
Big Pharma Advertising
The most common mode of advertising for Big Pharma companies remains to be television. With the increased presence of social media, digital and mobile advertising, ...
IMS report: Cancer drug spending increases to $100B
New IMS numbers show that global spending on cancer therapies have increased $75 billion in just the last 5 years with a 10.3% increase in ...
Mylan rejects Teva’s offer
Mylan has rejected a $40 billion offer from Teva to become the industry's biggest generic drug company. The reasoning behind the rejection was Mylan felt ...
Good news for GW Pharmaceutical’s epilepsy drug
New data from a Phase III study of GW Pharmaceuticals' in-development epilepsy drug shows a reduction the rates of seizures by more than 50%. The ...
Teva to buy Auspex
Teva announced that they have entered into a definitive merger agreement with Auspex Pharmaceuticals. Teva will pay $101 per share, or about $3.2 billion for ...
New Alzheimer's R&D project
With the number of people with dementia expected to triple by 2050, several industry giants are investing in a $100 million effort to find effective ...
Astellas awarded FDA approval
Astellas was awarded FDA approval for Cresemba, an antifungal treatment for two rare but dangerous infections that commonly affect patients undergoing chemotherapy or who have ...
Supply switch causing delays and cost changes for Genentech’ cancer drugs
A recent survey conducted by a hospital services company, Novation, has shown that since Genentech moved its best-selling cancer drugs to specialty distributors there have ...
Baxter Picks HQ Location for its Biopharma Spinoff
Baxalta Incorporated, will set up shop in a 260,000 square foot building located in Bannockburn, IL, a short 6 mile trip up the road from ...
Eisai gets an early FDA Approval
The FDA as awarded an early approval to Eisai for its new thyroid cancer drug. Lenvatinib, which will sell as Lenvima blocks the growth agent ...
- page 1 of 3 -